HVMN   Report issue

For profit
Founded: San Francisco CA United States (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2016
NCT02857829
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

HVMN Inc

Active Ingredients

Drugs in Other Trials (2)

caffeine (1 trial)

ketone monoester (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 2
  • # of Trial APIs: 2